Shared on08 Mar 25Fair value Decreased 67%
kapirey has decreased revenue growth from 20.0% to 11.0%, decreased profit margin from 40.0% to 35.0% and decreased future PE multiple from 30.0x to 19.0x.
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
kapirey's Fair Value
CHF 87.47
33.7% undervalued intrinsic discount08 Mar
CHF 58.00
1Y
-26.2%7D
1.6%